Position statement supports radiofrequency ablation, cryoablation, and microwave ablation as appropriate image-guided treatment options.
There’s new guidance available for percutaneous lung ablation from the Society of Interventional Radiology (SIR).
In an article published Aug. 1 in the Journal of Vascular and Interventional Radiology, experts shared recommendations for patient selection, treatment, and follow-up, as well as a patient safety quality-improvement guide.
Image-directed percutaneous ablation is widely used to treat various types of lung cancer in minimally invasive ways.
“Minimally invasive, image-guided thermal ablation offers patients with early stage, non-small-cell lung cancer, recurring lung cancer, and metastatic disease a safe and effective treatment option,” said statement author Mark Baerlocher, M.D., SIR’s standards division councilor and interventional radiologist at Royal Victoria Hospital in Ontario. “The two publications provide physicians with guidance [to]...[ensure] high-quality care that improves patients’ lives.”
Creation of the position statement was supported by the Canadian Association for Interventional Radiology, the Cardiovascular and Interventional Radiological Society of Europe, and the Society of Interventional Radiology. The statement itself was drafted by a team of interventional radiologists, oncologists, thoracic surgeons, and radiation oncologists.
Based on a literature review of 63 studies, the new recommendations are grounded in current evidence that points to the appropriateness of radiofrequency ablation, cryoablation, and microwave ablation as image-guided tools that can be used to treat primary and secondary lung cancer. They noted that lesion characteristics and risk mitigation should be used to choose which ablation method to use.
According to SIR President Mathew S. Johnson, M.D., FSIR, Gary J. Becker Professor of Radiology Research at Indiana University School of Medicine, publishing this evidence-based position statement is critical to improving patient outcomes. But, additional comparative studies on thermal ablation use in treating lung cancer will further strengthen guidance in the future.
For more coverage based on industry expert insights and research, subscribe to the Diagnostic Imaging e-Newsletter here.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
FDA Clears Point-Of-Care Ultrasound Platform and AI Software for Neuraxial Procedures
July 17th 2025The dual FDA clearances for the Accuro 3S point-of-care ultrasound device and the SpineNav-AI machine learning-based software may enhance precision and safety with ultrasound-guided neuraxial procedures.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.